NovaXS Biotech Corp.

led by a professional team in healthcare with a proven track record of over 40 million fundraising experience and 5 successful busines exits, novaxs biotech is on a mission to optimize patients’ medication self-administration experience and improve treatment outcomes. our patent-pending technology, telosis, is a patient-centric closed-loop drug delivery bio pharma solution that helps patients deliver medications subcutaneously or intramuscularly without a needle and manage their chronic condition and medication adherence on the patient engagement app. the technology could also help pharmaceutical partners reduce their cog by 30%, increase revenue with improved patient compliance, and boost efficacy of medication with better absorption rate. current partners and investors include baxter, edward-elmhurst health, helixmith, etc.